Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018

@inproceedings{Wright2018AustralasianSF,
  title={Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018},
  author={Edwina J. Wright and Andrew Grulich and Katy Roy and Mark A Boyd and Vincent Jasper Cornelisse and Darren B. Russell and Darryl O'Donnell and Bill Whittaker and Levinia Crooks and Iryna B Zablotska},
  booktitle={Journal of virus eradication},
  year={2018}
}
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine's (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control's PrEP guidelines and are designed to: •Support the… CONTINUE READING
8
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Effectiveness of oral pre-exposure prophylaxis ( PrEP ) for HIV

  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016